Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3025876 · 2 trials · 2 indications
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Possible drug-relatedness of an adverse event (AE) was in the opinion of the investigator. A summary of all serious and all other non-serious AEs, regardless of any possible causality, is located in the Reported Adverse Event Module.
| Arm | Type | Description |
|---|---|---|
| LY3025876 | EXPERIMENTAL | Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days. |
| Placebo | PLACEBO_COMPARATOR | Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days |
| LY3025876 + Liraglutide | EXPERIMENTAL | Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks. |
| Placebo + Liraglutide | PLACEBO_COMPARATOR | Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3025876 | DRUG | Administered SQ |
| Placebo | DRUG | Administered SQ |
| Liraglutide | DRUG | Administered SQ |
Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM) as determined by the investigator, controlled with diet or exercise alone or on a stable dose of metformin for at least 30 days * Have a body mass index (BMI) greater than or equal to 23 and less than or equal to 45 kilograms per sq...
LY3025876 is an investigational small molecule being studied for Type 2 Diabetes Mellitus and in healthy volunteers. It is in Phase 1 clinical development and is not approved by the FDA. Eli Lilly and Company (NYSE: LLY) is developing this drug.
LY3025876 is a small molecule being developed by Eli Lilly and Company. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its effects in Type 2 Diabetes Mellitus and in healthy volunteers.
LY3025876 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The drug is currently in Phase 1 clinical trials for Type 2 Diabetes Mellitus and healthy volunteer studies.
LY3025876 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Eli Lilly and Company is conducting early-stage trials to evaluate its safety and tolerability in healthy volunteers and in participants with Type 2 Diabetes Mellitus.
LY3025876 has been studied in two completed Phase 1 trials. NCT01528124 enrolled 41 healthy volunteers in Singapore, and NCT01870297 enrolled 72 participants with Type 2 Diabetes Mellitus in the United States. Both trials were randomized, double-blind, and placebo-controlled.
LY3025876 is the investigational code name for this drug developed by Eli Lilly and Company. No alternative brand names or other designations have been publicly associated with this compound in the clinical trial information available.